Keros Therapeutics, Inc.
KROS
$11.34
$0.312.81%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.46M | -7.28M | -30.70M | 148.45M | -46.03M |
| Total Depreciation and Amortization | 400.00K | 395.00K | 370.00K | 344.00K | 332.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.93M | 4.60M | 9.12M | 9.45M | 9.77M |
| Change in Net Operating Assets | -12.16M | 5.54M | -8.42M | 2.93M | -10.09M |
| Cash from Operations | -27.29M | 3.25M | -29.62M | 161.17M | -46.01M |
| Capital Expenditure | -134.00K | -132.00K | -720.00K | -565.00K | -289.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -134.00K | -132.00K | -720.00K | -565.00K | -289.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 127.00K | 140.00K | 17.00K | 4.00K | 75.54M |
| Repurchase of Common Stock | -378.90M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 139.00K | -- | -- | -- | 0.00 |
| Cash from Financing | -378.63M | 140.00K | 17.00K | 4.00K | 75.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -406.06M | 3.26M | -30.33M | 160.61M | 29.25M |